Jura Health and Samba Scientific Partner to Improve Genomic Testing Access to Underserved Populations
Jura Health, is pleased to announce that Samba Scientific has made a strategic investment in the company. Samba Scientific, a leading scientific marketing company, with expertise in demand creation for growth-stage companies, will help Jura reach more patients with low or no-cost access to rare disease testing and crucial guidance for next steps.
On average, it takes 6 years to get an accurate diagnosis for someone suspected of having a rare disease. During this time, a patient will typically see more than 16 physicians with an average cost of $220,000 to find the diagnosis. This doesn't have to be the case.
Jura Health dramatically shortens the lengthy diagnostic journey and reduces costs by providing at-home DNA sample collection, whole genome sequencing, and genetic counseling, delivering results in weeks rather than years. Covered by Medicaid in Colorado, the saliva-based test is accessible at no cost to Medicaid patients, including counseling and follow-up support, providing much-needed convenience and speed for rare disease patients.
Founded in 2018, Samba’s clients have included world-renowned organizations such as Twist Bioscience, Fabric Genomics, and Broad Clinical Labs, among others. As part of their agreement, Samba will advise and execute on Jura’s mission to provide genetic testing access for patients with rare diseases.
“Connecting directly with doctors and patients that will benefit from our solution requires specialized expertise. Samba’s capabilities in both direct-to-provider and direct-to-consumer promotion will allow Jura Health to significantly reduce the time it takes to drive market adoption in Colorado and other states. We are delighted to accelerate the delivery of our rare disease testing solutions to at-risk communities because of this strategic partnership with Samba Scientific,” said Chris Moore, CEO of Jura Health.
"Genetic testing for rare diseases has been around for a long time, but despite drops in costs and the massive improvements in sequencing technology, the patients that stand to benefit the most are still largely unable to access this technology,” said Jason Amsbaugh, CEO of Samba Scientific. “Jura Health is solving this urgent and persistent problem in our healthcare system in a way that is both elegant and practical, by bringing Whole Genome Sequencing and clinical guidance to the long-suffering rare disease community and those who care for them, including members of that community that have been consistently underserved. We are excited to partner with Jura and bring our full expertise to bear as a partner in their effort to reach those in need.”
